Skip to main content

Drug Interaction Report

7 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Major

ibuprofen lithium

Applies to: famotidine / ibuprofen, lithium

MONITOR CLOSELY: Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase serum lithium levels and induce toxicity in some patients. The exact mechanism of interaction is unknown, but is thought to involve inhibition of renal prostaglandin synthesis by NSAIDs, resulting in decreased renal blood flow and lithium excretion. There have been numerous published reports of lithium toxicity, including severe cases, following the introduction of various NSAIDs including diclofenac, ibuprofen, indomethacin, ketorolac, mefenamic acid, piroxicam, and COX-2 inhibitors. However, pharmacokinetic studies have been somewhat inconsistent, with no significant effects reported for benoxaprofen and etodolac, and up to a 58% increase in serum lithium levels reported for indomethacin. Both decreased serum concentrations of lithium and no effect have been reported for sulindac and aspirin. The interaction is apparently subject to marked interpatient variability.

MANAGEMENT: Given the narrow therapeutic index of lithium, caution is advised during coadministration with NSAIDs, particularly in the elderly or patients with other risk factors (e.g., sodium restriction; renal impairment; congestive heart failure; dehydration; concomitant use of diuretics, ACE inhibitors, or angiotensin II receptor antagonists). Close monitoring for clinical signs of lithium toxicity is recommended if concomitant treatment with NSAIDs is required. Serum lithium levels should be checked every 4 to 5 days after starting an NSAID until the extent of any potential interaction can be evaluated. A reduction in lithium dosage may be needed in some cases. Renal function should also be monitored regularly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of lithium toxicity such as drowsiness, dizziness, confusion, muscle weakness, vomiting, diarrhea, polydipsia, polyuria, tinnitus, tremor, ataxia, and blurred vision.

References (44)
  1. Ragheb M, Ban TA, Buchanan D, Frolich JC (1980) "Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level." J Clin Psychiatry, 41, p. 397-8
  2. Ragheb M (1987) "Ibuprofen can increase serum lithium level in lithium-treated patients." J Clin Psychiatry, 48, p. 161-3
  3. Herschberg SN, Sierles FS (1983) "Indomethacin-induced lithium toxicity." Am Fam Physician, 28, p. 155-7
  4. Reimann IW, Diener U, Frolich JC (1983) "Indomethacin but not aspirin increases plasma lithium ion levels." Arch Gen Psychiatry, 40, p. 283-6
  5. Ragheb M, Powell AL (1986) "Lithium interaction with sulindac and naproxen." J Clin Psychopharmacol, 6, p. 150-4
  6. Furnell MM, Davies J (1985) "The effect of sulindac on lithium therapy." Drug Intell Clin Pharm, 19, p. 374-6
  7. Reimann IW, Frolich JC (1981) "Effects of diclofenac on lithium kinetics." Clin Pharmacol Ther, 30, p. 348-52
  8. Ragheb M (1990) "The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions." J Clin Psychopharmacol, 10, p. 350-4
  9. Khan IH (1991) "Lithium and non-steroidal anti-inflammatory drugs." Br Med J, 302, p. 1537-8
  10. Gadallah MF, Feinstein EI, Massry SG (1988) "Lithium intoxication: clinical course and therapeutic considerations." Miner Electrolyte Metab, 14, p. 146-9
  11. Kamlana SH, Kerry RJ, Khan IA (1980) "Lithium: some drug interactions." Practitioner, 224, p. 1291-2
  12. Ragheb M (1990) "The interaction of lithium with phenylbutazone in bipolar affective patients." J Clin Psychopharmacol, 10, p. 149-50
  13. Walbridge DG, Bazire SR (1985) "An interaction between lithium carbonate and piroxicam presenting as lithium toxicity." Br J Psychiatry, 147, p. 206-7
  14. Shelley RK (1987) "Lithium toxicity and mefenamic acid: a possible interaction and the role of prostaglandin inhibition." Br J Psychiatry, 151, p. 847-8
  15. MacDonald J, Neale TJ (1988) "Toxic interaction of lithium carbonate and mefenamic acid." Br Med J, 297, p. 1339
  16. Nadarajah J, Stein GS (1985) "Piroxicam induced lithium toxicity." Ann Rheum Dis, 44, p. 502
  17. Kerry RJ, Owen G, Michaelson S (1983) "Possible toxic interaction between lithium and piroxicam." Lancet, 1, p. 418-9
  18. (2002) "Product Information. Eskalith (lithium)." SmithKline Beecham
  19. Harrison TM, Davies DW, Norris CM (1986) "Lithium carbonate and piroxicam." Br J Psychiatry, 149, p. 124-5
  20. Shelley RK (1986) "Lithium and piroxicam." Br J Psychiatry, 148:, p. 343
  21. Langlois R, Paquette D (1994) "Increased serum lithium levels due to ketorolac therapy." Can Med Assoc J, 150, p. 1455-6
  22. Iyer V (1994) "Ketorolac (Toradol) induced lithium toxicity." Headache, 34, p. 442-4
  23. Brouwers JRBJ, Desmet PAGM (1994) "Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs." Clin Pharmacokinet, 27, p. 462-85
  24. Stockley IH (1995) "Interactions between lithium and NSAIDs." Can Med Assoc J, 152, p. 152-3
  25. Finley PR, Warner MD, Peabody CA (1995) "Clinical relevance of drug interactions with lithium." Clin Pharmacokinet, 29, p. 172-91
  26. Hughes BM, Small RE, Brink D, Mckenzie ND (1997) "The effect of flurbiprofen on steady-state plasma lithium levels." Pharmacotherapy, 17, p. 113-20
  27. Chandragiri SS, Pasol E, Gallagher RM (1998) "Lithium, ACE inhibitors, NSAIDs, and verapamil - A possible fatal combination." Psychosomatics, 39, p. 281-2
  28. Turck D, Heinzel G, Luik G (2000) "Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam." Br J Clin Pharmacol, 50, p. 197-204
  29. Lundmark J, Gunnarsson T, Bengtsson F (2002) "A possible interaction between lithium and rofecoxib." Br J Clin Pharmacol, 53, p. 403-4
  30. Monji A, Maekawa T, Miura T, et al. (2002) "Interactions between lithium and non-steroidal antiinflammatory drugs." Clin Neuropharmacol, 25, p. 241-2
  31. (2003) "A life-threatening interaction between lithium and celecoxib." Br J Clin Pharmacol, 55, p. 413
  32. Gunja N, Graudins A, Dowsett R (2002) "Lithium toxicity: a potential interaction with celecoxib." Intern Med J, 32(9-10), p. 494
  33. Bennett WM (1997) "Drug interactions and consequences of sodium restriction." Am J Clin Nutr, 65, S678-81
  34. Alderman CP, Lindsay KS (1996) "Increased serum lithium concentration secondary to treatment with tiaprofenic acid and fosinopril." Ann Pharmacother, 30, p. 1411-3
  35. Phelan KM, Mosholder AD, Lu S (2003) "Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs." J Clin Psychiatry, 64, p. 1328-34
  36. Juurlink DN, Mamdani MM, Kopp A, Rochon PA, Shulman KI, Redelmeier DA (2004) "Drug-induced lithium toxicity in the elderly: a population-based study." J Am Geriatr Soc, 52, p. 794-8
  37. Ratz Bravo AE, Egger SS, Crespo S, Probst WL, Krahenbuhl S (2004) "Lithium intoxication as a result of an interaction with rofecoxib." Ann Pharmacother, 38, p. 1189-93
  38. Wilting I, Movig KL, Moolenaar M, et al. (2005) "Drug-drug interactions as a determinant of elevated lithium serum levels in daily clinical practice." Bipolar Disord, 7, p. 274-80
  39. Chen L, Pym H (2010) "Rapid onset of neurological symptoms and lithium toxicity on starting meloxicam." Aust N Z J Psychiatry, 44, p. 95
  40. De Winter S, Meersseman W, Verelst S, Willems L, Spriet I (2013) "Drug-related admissions due to interaction with an old drug, lithium." Acta Clin Belg, 68, p. 356-8
  41. Finley PR (2016) "Drug interactions with lithium: an update." Clin Pharmacokinet, 55, p. 925-41
  42. Hassan S, Khalid F, Alirhayim Z, Amer S (2013) "Lithium toxicity in the setting of nonsteroidal anti-inflammatory medications." Case Rep Nephrol, 2013, epub
  43. Frolich JC, Leftwich R, Ragheb M, Oates JA, Reimann I, Buchanan D (1979) "Indomethacin increases plasma lithium." Br Med J, 1, p. 1115-6
  44. Kelly CB, Cooper SJ (1991) "Toxic elevation of serum lithium concentration by non-steroidal anti-inflammatory drugs." Ulster Med J, 60, p. 240-2
Moderate

lithium famotidine

Applies to: lithium, famotidine / ibuprofen

MONITOR: Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. According to the manufacturer, prolongation of the QT interval has been reported very rarely in patients with impaired renal function whose dose/dosing interval of famotidine may not have been adjusted appropriately. In general, the risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.

References (3)
  1. (2002) "Product Information. Pepcid (famotidine)." Merck & Co., Inc
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."
Minor

ibuprofen famotidine

Applies to: famotidine / ibuprofen, famotidine / ibuprofen

H2 antagonists may alter the pharmacokinetic disposition of some nonsteroidal anti-inflammatory drugs (NSAIDs), resulting in increased or decreased plasma concentrations. Data have been varied, even for the same NSAID. The mechanism may involve inhibition of metabolism, changes in gastric pH resulting in altered absorption, and/or reduced urinary elimination of the affected NSAIDs. Statistically significant changes have been small and of limited clinical significance when interactions have been observed.

References (5)
  1. Said SA, Foda AM (1989) "Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man." Arzneimittelforschung, 39, p. 790-2
  2. Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS (1986) "Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine." Eur J Clin Pharmacol, 31, p. 371-4
  3. (2001) "Product Information. Daypro (oxaprozin)." Searle
  4. "Product Information. DurAct (bromfenac)." Wyeth-Ayerst Laboratories
  5. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Drug and food interactions

Moderate

lithium food

Applies to: lithium

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Moderate

ibuprofen food

Applies to: famotidine / ibuprofen

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References (1)
  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
Moderate

lithium food

Applies to: lithium

MONITOR: One study has suggested that caffeine withdrawal may significantly increase blood lithium levels. The mechanism may be involve reversal of a caffeine-induced increase in renal lithium excretion.

MANAGEMENT: When caffeine is eliminated from the diet of lithium-treated patients, caution should be exercised. When caffeine consumption is decreased, close observation for evidence of lithium toxicity and worsening of the psychiatric disorder is recommended. Patients should be advised to notify their physician if they experience symptoms of possible lithium toxicity such as drowsiness, dizziness, weakness, ataxia, tremor, vomiting, diarrhea, thirst, blurry vision, tinnitus, or increased urination.

References (1)
  1. Mester R, Toren P, Mizrachi I, Wolmer L, Karni N, Weizman A (1995) "Caffeine withdrawal increases lithium blood levels." Biol Psychiatry, 37, p. 348-50
Minor

famotidine food

Applies to: famotidine / ibuprofen

H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.

References (1)
  1. Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.